Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock closed at $396.64 on 12/19/24 after a major decline of -11.4%. Moreover, this decline was accompanied by exceptionally high trading volume at 596% of normal. The stock has declined -15.3% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Vertex Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Vertex Pharmaceuticals has a neutral Appreciation Score of 56 but a good Power Rating of 72, and the Positive Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment